PALM BEACH GARDENS, Fla., & NEEDHAM, Mass.--(BUSINESS WIRE)--Tyrogenex, a privately held biopharmaceutical company, today announced that data from its Phase I study of X-82, an oral dual anti-VEGFR/PDGFR tyrosine kinase inhibitor, with everolimus in solid tumors will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2016, which is being held from June 3 - 7, 2016 in Chicago, Illinois. The presentation details are as follows:
